By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
19 Peculiar Films You Shouldn't Watch With Your Mum - 2Portugal among EU countries with the most people working close to 50 hours a week
- 3Israel reports second missile fire from Yemen since start of Iran war
- 46 Fun Urban areas For Seniors To Travel
- 54 Sound blocking Earphones for Prevalent Sound and Solace
- Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes
- Explosions heard across Tehran after IDF announces wave of strikes on regime terror targets
- Collierville residents with no power as temperatures plunge
- Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- Don’t let food poisoning crash your Thanksgiving dinner
- Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
